

OptimalCare for cardiology

Evidence driven ~ Better outcomes ~ Lower cost

Screening and testing

- Routine ischemia testing is not indicated in stable CAD.^{1,2}
- Treadmill Exercise Stress Test (EST) is the most cost-effective test when the ECG is normal, and patents are able to exercise on the treadmill. In most others, CCTA/FFR will be the optimal test.
- Preoperative ischemia testing is not needed in patients who can achieve 4 METS (climb one flight of stairs, grocery shopping with cart) of activity without CV symptoms.
- Screening for asymptomatic carotid stenosis is not indicated.
- Cerebrovascular imaging is rarely indicated for syncope.

Atrial fibrillation management

- 27% of AF patients are anticoagulated inappropriately and the decision to treat should be based upon CHA2DS2VASc score of ≥ 2 in men and ≥ 3 in women. Use shared decision-making at lower scores if anticoagulation is considered.
- Multiple observational studies have shown both the lowest stroke rate and lowest bleeding rates with apixaban compared to other DOACs.
- In the absence of systolic CHF, rate control and rhythm control for AF have equal outcomes.³
- Recurrence of AF post ablation is 30-50% at 5 years.

Medical management

- LDL levels can be reduced up to 70% with rosuvastatin/ezetimibe.
- · PCSK-9 inhibitors are infrequently needed.
- Peripheral Artery Disease (PAD) is optimally managed with risk factor control in the absence of lifestyle limiting symptoms.
- · Aldosterone blockade or amiloride are the most effective therapies for resistant hypertension.
- Syncope may be mismanaged; refer to the algorithm in the Cleveland Clinic Journal of Medicine for optimal management.⁴ (Figure 1. Management of syncope)
- Echo for Patent Foramen Ovale is indicated for cryptogenic stroke under age 60.5

Cardiovascular disease approach

Extensive testing has become the standard and prevention management is more valuable than invasive therapies.

Shared decision-making:

- · Obtain palliative care evaluation prior to Transcatheter Aortic Valve Replacement (TAVR) in the frail elderly.
- · Use prior to defibrillator placement.

CHF management:

- Daily weights are the most impactful way to monitor CHF.
- Aldosterone inhibitors are underutilized in systolic Class III/IV CHF and reduce mortality by 11% in two years.⁶
- Entresto (sacubitril/valsartan) modestly effective for systolic Class III/IV CHF at a cost of \$4,400 yearly.
- 1. The New England Journal of Medicine, 373(20), 1937-1946. doi:10.1056/NEJMoa1505532
- 2. The Lancet, 391(10115), 31-40. doi:10.1016/S0140-6736(17)32714-9
- 3. NEJM. 378. 417-427. doi:10.1056/NEJMoa1707855
- 4. Cleveland Clinic Journal of Medicine, 12, 755-766. Retrieved from https://www.mdedge.com/ccjm/article/89311/cardiology/syncope-etiology-and-diagnostic-approach
- 5. NEJM, 377, 1033-1042. doi:10.1056/NEJMoa1707404
- 6. NEJM, 341, 709-717. doi:10.1056/NEJM199909023411001

This information is for informational purposes and should only be used by licensed clinicians to aid in improving diagnosis, detection and/or clinically appropriate treatment; this information is not a substitute for clinical decision-making and should not be used to make individualized diagnostic or treatment decisions for specific patients. These materials do not necessarily represent the standard of care for treating a particular condition; rather; the content is a synthesis of current evidence for consideration by a trained clinician when evaluating a patient.

Content updated: 1/2021 Version: 6/2022